Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2015/01/30 15:23
2015/01/30 15:23
1m
CTI Biopharma is conducting two phase III studies of pacritinib in myelofibrosis. The first study -- the one we're discussing here -- is designed with a relatively low bar for success. Pacritinib is...
2015/01/30 15:23
2015/01/30 15:23
Latest videos
2015/01/28 20:22
2015/01/28 20:22
1d
These are all the questions waiting for answers when Regulus updates the RG-101 study in early February. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he...
2015/01/12 19:22
2015/01/12 19:22
17d
Updated with additional information from 1:35 pm EST SAN FRANCISCO ( TheStreet) -- MannKind(MNKD) CEO Al Mann is retiring and the company's inhaled insulin device Afrezza still has no publicly...
2015/01/12 15:22
2015/01/12 15:22
17d
The Duchenne muscular dystrophy (DMD) patients continue to walk more than three years after starting treatment with eteplirsen, with no significant side effects or tolerability issues. The drug...
2015/01/12 11:22
2015/01/12 11:22
18d
Vertex Pharmaceuticals(VRTX) announced its 2015 business outlook on Sunday night, ahead of Monday's presentation at the J.P. Morgan Healthcare Conference. There were a some interesting tidbits...
2015/01/12 05:22
2015/01/12 05:22
18d
BEDMINSTER, NJ (TheStreet) -- NPS Pharmaceuticals(NPSP) and Aegerion Pharmaceuticals(AEGR) secured U.S. approval for their respective rare-disease drugs within three days of each other in December...
2015/01/09 20:22
2015/01/09 20:22
20d
Gilead, Express Scripts May Be Movers Next Week Amid Healthcare Conference TheStreet senior columnist Adam Feuerstein previews what to watch at the J.P. Morgan Healthcare Conference, which kicks off...
2015/01/08 14:22
2015/01/08 14:22
22d
Investor expectations for the anti-LINGO-1 data in patients with acute optic neuritis were on the low side, so expect Wall Street to expend considerable time interpreting the mixed bag of actual...
2015/01/05 04:22
2015/01/05 04:22
25d
So far, solithromycin's safety profile looks relatively clean. From Cempra's Sunday press release: In this clinical trial, serious adverse events (SAEs) occurred with equal frequency in both arms (...
2015/01/02 14:22
2015/01/02 14:22
28d
Once again, biotech stocks greatly outperformed the broader market in 2014. The 10 best-performing biotech and drug stocks in 2014: Twenty-eight biotech and drugs stocks grew their market caps to $1...
2015/01/30 15:23
2015/01/30 15:23
Latest from Twitter